Literature DB >> 25941193

Cytokines: Names and Numbers You Should Care About.

Stephen R Holdsworth1, Poh-Yi Gan2.   

Abstract

Cytokines play an important role in host defense against microorganisms. They orchestrate innate immunity by inducing protective local inflammation and systemic acute phase responses. Cytokines are important in initiating, amplifying, directing, mediating, and regulating adaptive immunity. Unfortunately, they may also direct tissue damage if excessive responses occur or if they are involved in directing and mediating autoimmunity. Under these circumstances, cytokines are potential therapeutic targets. Over the last 20 years, we have seen the successful development and clinical implementation of biologic strategies that target key cytokines in specific inflammatory diseases with efficacy, specificity, and toxicity profiles challenging conventional drug therapies. These therapies are finding new applications and many new agents show promise. Unfortunately, these new cytokine-based therapies have had little effect on renal disease. This review provides evidence that common renal diseases, including those causing AKI and the autoimmune proliferative and crescentic forms of GN, have cytokine mediation profiles that suggest they would be susceptible to cytokine-targeting therapeutic strategies.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  clinical trial; cytokines; nephrology

Mesh:

Substances:

Year:  2015        PMID: 25941193      PMCID: PMC4670773          DOI: 10.2215/CJN.07590714

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  98 in total

1.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

2.  Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.

Authors:  Xuebing Feng; Hui Wu; Jennifer M Grossman; Punchong Hanvivadhanakul; John D FitzGerald; Grace S Park; Xin Dong; Weiling Chen; Michelle H Kim; Haoling H Weng; Daniel E Furst; Alan Gorn; Maureen McMahon; Mihaela Taylor; Ernest Brahn; Bevra H Hahn; Betty P Tsao
Journal:  Arthritis Rheum       Date:  2006-09

3.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Mark C Genovese; Theresa K Musser; Elliott B Grossbard; Daniel B Magilavy
Journal:  N Engl J Med       Date:  2010-09-22       Impact factor: 91.245

4.  An open study of oxpentifylline in early rheumatoid arthritis.

Authors:  P D Kiely; D Johnson; B E Bourke
Journal:  Br J Rheumatol       Date:  1998-09

5.  Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury.

Authors:  J Deng; Y Kohda; H Chiao; Y Wang; X Hu; S M Hewitt; T Miyaji; P McLeroy; B Nibhanupudy; S Li; R A Star
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

6.  NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury.

Authors:  Hyun-Jung Kim; Dong Won Lee; Kameswaran Ravichandran; Daniel O Keys; Ali Akcay; Quocan Nguyen; Zhibin He; Alkesh Jani; Danica Ljubanovic; Charles L Edelstein
Journal:  J Pharmacol Exp Ther       Date:  2013-07-05       Impact factor: 4.030

7.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

8.  Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation.

Authors:  Konstantia-Maria Chavele; Deepa Shukla; Tracey Keteepe-Arachi; Judith Anna Seidel; Dietmar Fuchs; Charles D Pusey; Alan D Salama
Journal:  Arthritis Rheum       Date:  2010-05

9.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Authors:  P J Charles; R J Smeenk; J De Jong; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  2000-11

10.  Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.

Authors:  Michelle Petri; Daniel J Wallace; Alberto Spindler; Vishala Chindalore; Kenneth Kalunian; Eduardo Mysler; C Michael Neuwelt; Gabriel Robbie; Wendy I White; Brandon W Higgs; Yihong Yao; Liangwei Wang; Dominique Ethgen; Warren Greth
Journal:  Arthritis Rheum       Date:  2013-04
View more
  38 in total

Review 1.  T Cells: Soldiers and Spies--The Surveillance and Control of Effector T Cells by Regulatory T Cells.

Authors:  Bruce M Hall
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-15       Impact factor: 8.237

2.  The Complex Role of Interleukin 6 in Regulating T-cell Responses during Acute Glomerulonephritis.

Authors:  Sarah Cormican; Matthew D Griffin
Journal:  J Am Soc Nephrol       Date:  2019-07-16       Impact factor: 10.121

Review 3.  Cytokines and chemokines involved in the defense reaction against HIV-1 and hepatitis B virus: isn't it time to use a standardized nomenclature of the involved mediators?

Authors:  Lutz G Gürtler
Journal:  Virus Genes       Date:  2019-12-17       Impact factor: 2.332

4.  The Orphan Cytokine Receptor CRLF3 Emerged With the Origin of the Nervous System and Is a Neuroprotective Erythropoietin Receptor in Locusts.

Authors:  Nina Hahn; Luca Büschgens; Nicola Schwedhelm-Domeyer; Sarah Bank; Bart R H Geurten; Pia Neugebauer; Bita Massih; Martin C Göpfert; Ralf Heinrich
Journal:  Front Mol Neurosci       Date:  2019-10-11       Impact factor: 5.639

Review 5.  The Intersection of Acute Kidney Injury and Non-Coding RNAs: Inflammation.

Authors:  Bojun Li; Fangyou Lin; Yuqi Xia; Zehua Ye; Xinzhou Yan; Baofeng Song; Tianhui Yuan; Lei Li; Xiangjun Zhou; Weimin Yu; Fan Cheng
Journal:  Front Physiol       Date:  2022-06-09       Impact factor: 4.755

6.  The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects.

Authors:  Lirit N Franks; Benjamin M Ford; Toshifumi Fujiwara; Haibo Zhao; Paul L Prather
Journal:  Toxicol Appl Pharmacol       Date:  2018-06-12       Impact factor: 4.219

7.  Myeloperoxidase instigates proinflammatory responses in a cecal ligation and puncture rat model of sepsis.

Authors:  Hong Yu; Yajun Liu; Meifang Wang; Ricardo J Restrepo; Derek Wang; Theodore J Kalogeris; William L Neumann; David A Ford; Ronald J Korthuis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-08-07       Impact factor: 4.733

8.  Early detection of acute kidney injury after pediatric cardiac surgery.

Authors:  John Lynn Jefferies; Prasad Devarajan
Journal:  Prog Pediatr Cardiol       Date:  2016-06

9.  Exercise for Toxicity Management in Cancer-A Narrative Review.

Authors:  Ian R Kleckner; Richard F Dunne; Matthew Asare; Calvin Cole; Fergal Fleming; Chunkit Fung; Po-Ju Lin; Karen M Mustian
Journal:  Oncol Hematol Rev       Date:  2018-02-15

10.  Human Adipose Stem Cells (hASCs) Grown on Biodegradable Microcarriers in Serum- and Xeno-Free Medium Preserve Their Undifferentiated Status.

Authors:  Francesco Muoio; Stefano Panella; Valentin Jossen; Matias Lindner; Yves Harder; Michele Müller; Regine Eibl; Tiziano Tallone
Journal:  J Funct Biomater       Date:  2021-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.